Dr. Reddy's Laboratories, Incorporated

Genentech, Inc.

Optimer Pharmaceuticals, Inc.

Genetech, Inc.

Durect Corporation

Primus Pharmaceuticals, Inc.

Latitude Pharmaceuticals, Inc.

Promius Pharma LLC

Merck Sharp + Dohme Corp.

Webb, Julie Ann

Sabino, Rafael Anthony

Chu, Jan-jon

Chen, Andrew Xian

Okumu, Franklin

Franklin W Okumu

Jeffrey L Cleland

Andrew Xian Chen

Sateesh Kandavilli

Youe-Kong Shue

Hailiang Chen

Sujit Kumar Dolai

Dushyanth Surakanti

Manish M Bankar

Ellen Filvaroff

Xanthe M Lam

Vijendra Nalamothu

Chan-Kou Hwang

Yu-Hung Chiu

Alex Romero

Jonathan James Duffield

Jan-Jon Chu

Farah Kondori Babakhani

Yuan-Ting Chen

Mei-Chiao Wu

Pamela Sears

Rafael Anthony Sabino

Julie Ann Webb

Madhusudhan Bommagani

Chi-Jen Frank Du

Priyadarshani Sahukar

Ming-His Chiou

Manish M Banker

Ming-Hsi Chiou

Starr Louise Miller-Shangle

Amalavoyal Raghav Chari

Pamela Suzanne Sears

Robert Brian Walsh

Topical compositions comprising a corticosteroid, at least one alcohol, and a penetration enhancing agent.

Topical compositions comprising a corticosteroid

The present application relates to topical compositions. In particular, the present application relates to a topical composition comprising retinoid as active agent, and pharmaceutically acceptable excipient(s), and a process of preparing such compositions. Further, the present application relates to method of using topical compositions for the treatment of skin disorders such as acne, rosacea, psoriasis etc.

Topical retinoid compositions

The present application provides parenteral compositions of diclofenac or its pharmaceutically acceptable salt and methods for making and using such compositions. Some of the compositions of the present application has one or more following properties: (1) ready to be injectable, (2) in the form of an oil-in-water emulsion, (3) stable under appropriate storage conditions, (4) containing therapeutically effective amount of diclofenac or its pharmaceutically acceptable salt, (5) sterilizable by filtration (6) containing components acceptable by regulatory agencies (e.g. the FDA), (7) containing low oil content and thus not exacerbating hyerlipidemia, and (8) is neither hyperallergenic nor vein irritating.

Parenteral diclofenac composition

Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.

Parenteral compositions of celecoxib

Topical compositions comprising a corticosteroid and at least one penetration enhancing agent, wherein the composition is substantially free of propylene glycol.

The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same.

Phospholipid depot

Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the speciessubspecieshaving the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.

Tiacumicin production

The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specificallyinfections.

18-membered macrocycles and analogs thereof

A composition for administration of a beneficial agent, contains a solvent mixture including a hydrophobic solvent and a hydrophilic solvent; a bioerodible polymer; and a beneficial agent. The polymer and the beneficial agent are dissolved. The composition has a low viscosity, allowing for easy injection through standard hypodermic needles.

Bioerodible polymers for injection

Growing community of inventors

San Diego, CA, United States of America

Franklin W Okumu